BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances

blonca9
Nov 21, 2023
1 min read

Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 that will read in ADH1 early next year, and the draw to invest in early science.

Recent Posts

See All

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

AI news: Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight